An examination of the pattern of lipid biosynthetic responses to isoniazid (INH) treatment of Mycobacterium tuberculosis and Mycobacterium smegmatis suggests that the mode of action of activated INH differs between these 2 organisms. Transformation of M. smegmatis with inhA on a plasmid construct conferred high-level resistance to INH, while the same construct failed to confer resistance upon M. tuberculosis. The inhA region from 2 clinical isolates whose resistance has been attributed to changes in the upstream promoter region has been cloned and was not sufficient to impart INH resistance to the level of the parent strain on sensitive M. tuberculosis. These putative mutant promoter elements appear to elevate expression levels of gene fusion reporter constructs, suggesting some noncausal connection between the observed mutations and the lipid metabolism of drug-resistant organisms. These results suggest that InhA is not the major target for activated INH in M. tuberculosis.
Isoniazid (INH) is a front-line antituberculosis drug with high specificity for tubercle bacilli [1] . MICs for sensitive Mycobacterium tuberculosis generally range from 0.02 to 0.05 j.tg/mL, while MICs for other mycobacterial species range from 5 to 50 j.lg/mL [2] . MICs for gram-negative organisms are even higher. Escherichia coli, for example, is resistant to at least 500 ,ug/mL INH [3] . This specificity has provided the foundation for a wealth of biochemical studies aimed at elucidating the mechanism of action of INH [4] . These studies have shown that INH is a prodrug that requires activation by an endogenous mycobacterial enzyme, KatG [5, 6] . The importance of KatG mutations in INH resistance is well established, although the extent to which such mutations account for the spectrum of resistance observed in clinical isolates is arguable [7] . Best estimates indicate that> 50% of INH-resistant clinical isolates are katG mutants [8] .
The reactive species formed upon INH activation is unclear, but the molecular target of this activated species has been shown to lie in the biosynthetic pathway for the unique mycobacterial lipids, the mycolic acids [9] . Studies by Takayama and coworkers [10, 11] in M. tuberculosis have demonstrated clearly that INH inhibits the synthesis of unsaturated fatty acids containing~26 carbons and that treatment results in the accumulation of saturated fatty acids of the corresponding length.
These results suggest that the target of activated INH in M tuberculosis is an enzyme involved in the production of an unsaturated 24-carbon fatty acid.
The possibility of improving both chemotherapeutic options and the diagnosis ofINH resistance in the treatment oftuberculosis has prompted a detailed examination of the mechanism of INH action. Recently, a genetic approach revealed a protein that, when hyperexpressed, conferred INH resistance on Mycobacterium smegmatis [12] . This protein, InhA, has been shown to catalyze in vitro the reduction of 2-trans-octenoyl-acyl carrier protein as well as enoyl coenzyme A (CoA) esters of varying lengths, with an apparent preference for 2-trans-hexadecenoyl CoA [13] . Thus, InhA appears to function as a component of a type II fatty acid synthase system responsible for the final reduction step in chain elongation to form conventional fatty acids [14, 15] . InhA is therefore apparently not the longchain 24-carbon fatty acid desaturase suggested by the M. tuberculosis biochemical data. To explain the apparent discrepancy between the biochemically identified target and the target identified through complementation ofM. smegmatis, we investigated the association between InhA and INH resistance in M. tuberculosis.
Materials and Methods
Lipid pulse-labeling and analysis. M. tuberculosis H37Rv (TMC 102) and M. smegmatis mc 2 155 were grown in Middlebrook 7H9 medium with albumin-dextrose-catalase (ADC) supplement (Remel, Lenexa, KS) and 0.05% Tween 80 (7H9-ADC-Tween) to an optical density (OD) at 650 nm of 0.1. INH was added to the indicated concentration, and the culture was incubated for I h at 3TC. Subsequently, 50 /-lCi of [1- 14C]acetic acid was added, and the culture was incubated for an additional 15 min at 37°e. Saponification of total lipids and LH-20 column analysis were done as previously described [10] . Elution time of fatty acids of known acyl chain length was determined using synthetic standards of various fatty acids obtained from Aldrich Chemical (St. Louis) followed by thin-layer chromatography analysis of LH-20 column fractions [10] . Library preparation and screening. InhA selection from an M. tuberculosis library was done by size-fractionating Sau3aI partial digestions of M. tuberculosis chromosomal DNA followed by ligation of different size classes of inserts into dephosphorylated pMV206H (pMV206H is identical to pMV206 with a hygromycin marker replacing the kanamycin-resistance determinant). Ligation of these inserts resulted in >90% of plasmids containing inserts that still transformed efficiently into M tuberculosis. Insert diversity was examined by restriction digestion of individual clones from this library. InhA-containing clones were obtained from libraries carrying both 1-to 3-and 5-to 7-kb inserts by electroporation followed by plating onto hygromycin (50 ,ug/mL) and INHcontaining (various concentrations) 7Hll medium. Recovery times following electroporation were 2 h for M smegmatis and 24 h for M. tuberculosis. In each transformation, efficiency was checked by plating onto 7Hll medium containing only hygromycin. Plasmid DNA was prepared from INH-resistant M. smegmatis by using plasmid kits (Qiagen, Chatsworth, CA).
Cloning and sequencing inhA loci. For reporter gene assays, various inhA promoter regions were amplified by polymerase chain reaction (PCR) using UITma DNA polymerase (Perkin-Elmer, Foster City, CA) and cloned as fusions with the firefly luciferase (lux) gene. The amplified region, which extended from 464 bp upstream to 65 bp downstream of the open-reading frame 1 (ORF1) start codon, was cloned into the dual reporter gene construct pMH66 using 50 ,ug/mL hygromycin to select for transformants. Plasmid pMH66 is an integrating mycobacterial shuttle vector with lacZ expression driven by a constitutive synthetic promoter and a polylinker upstream of the lux gene for introduction of promoter fragments of interest. To study the expression of mutant inhA loci in mycobacteria, the entire 2100-bp inhA locus, from 464 bp upstream of the ORFI start codon to 29 bp downstream of the inhA stop codon, was amplified as above and cloned directly into the integrating vector pMV306. The DNA sequence of all regions amplified by PCR was determined, confirming the absence ofPCRinduced sequence errors. DNAs were introduced into M. tuberculosis H37Rv or M. smegmatis by electroporation [12] .
Promoter activity measurements. M. smegmatis (mc 2155) containing the luxllacZ reporter plasmids were diluted to an OD at 540 nm of 0.025 and grown for 4 h at 37°C in 7H9-ADC-Tween medium. Duplicate 50-,uL aliquots were assayed for luciferase activity (AutoLumat luminometer model 96P; Wallac Instruments, Gaithersburg, MD) as described [16] . For ,B-galactosidase assays, bacteria were transferred to a 0.5-mL tube containing 200 mg of O. I-mm glass beads and lysed by shaking in a Bead-Beater apparatus (BioSpec Products, Bartlesville, OK) at medium speed for 45 s. ,B-galactosidase activity was determined from duplicate IO-IlL aliquots of lysate by chemiluminescent assay (Galacto-Light; Tropix, Bedford, MA), following the manufacturer's protocol.
MIC determinations. These were done in several ways and were always referenced to an H37Rv control.
For determining MICs in broth, 7H9-ADC-Tween cultures were subcultured to an initial 00 at 650 nm of 0.05 in the presence of the indicated amount of INH. Growth was monitored by measuring the 00 every 24 h for 5 days total (for M. tuberculosis) or every 2 h for 24 h total (for M. smegmatis). Unless otherwise indicated, recombinant organisms were grown in the presence of 50 ,ug/ mL hygromycin. Percent survival was the percent change in OD compared with OD of the same culture subcultured without any added INH.
For determining MICs on plates, the indicated concentration of sterile INH was incorporated into 7H 11 base after cooling to 50°C and was compared with the growth of a reference strain (H37Rv), as previously described [17] .
Evaluation of blinded samples by an independent clinicallaboratory (Specialty Laboratories, Santa Monica, CA) using a standard radiometric assay method confirmed our results.
Results

Lipid biosynthetic responses to INH treatment in M. tuberculosis and M. smegmatis.
Since the biochemical data supporting a 24-carbon desaturase as the target in M. tuberculosis was largely based on the response of intracellular pools of lipids thought to be precursors of mycolic acids, we decided to compare the lipid biosynthetic response of M. smegmatis and M. tuberculosis [10] . In M. tuberculosis (figure lA, top, middle) INH treatment at levels near the MIC (0.1-1 ,ug/mL) results in an immediate accumulation of 24-and 26-carbon fatty acids. It was previously reported [10] that these acids are primarily saturated 24-and 26-carbon fatty acids, suggesting that the target was the 24-carbon fatty acid desaturase. At concentrations of up to 10 ,ug/mL, the profiles look quantitatively and qualitatively the same (figure l A, bottom).
In M. smegmatis, the profile is very different, with little effect at 1 ,ug/mL (figure IB, middle) and an inhibition of short-chain fatty acid metabolism at 10 ,ug/mL INH (again, a level near the MIC for this species). No accumulation of 24-or 26-carbon fatty acids is seen in M. smegmatis at any concentration of INH. The M. smegmatis profiles are consistent with an inhibition of short-chain fatty acid biosynthesis by INH (presumably via inhibition of InhA), with mycolic acid biosynthesis only secondarily affected as the pool of precursors diminishes. In contrast, the M tuberculosis lipid data suggest that INH directly inhibits desaturation of tetra-or hexacosanoic acids.
Multiple 5 cfu/ug for M. tuberculosis). Ten M. tuberculosis H37Rv colonies transformed with purified InhAcontaining plasmid selected first on hygromycin alone were also replated onto lower INH concentrations (down to 0.1 f.lgl mL) in both broth and solid medium, but no significant improvement in growth could be observed at these levels compared with growth in controls.
InhA promoter mutations can affect promoter strength in M. smegmatis. The scarcity of mutations in the coding region of inhA [8] and the proximity of an upstream gene (ORFl) has led to an examination of the role of upstream noncoding sequences that may playa role in regulating transcription of both inhA and ORF 1. It has been proposed that noncoding region mutations, observed in some INH-resistant clinical isolates, cause overexpression of InhA and consequently confer INH resistance to these strains [7, 12, 18] .
To test this hypothesis, the inhA promoter region was amplified by PCR from wild type M. tuberculosis and from 3 clinical isolates containing mutations in this region. The promoter mutations were verified by sequence analysis and are shown in table 1, along with the level of resistance of the parent strain.
To examine whether these mutations affected expression levels of the putative operon, they were cloned into a dual reporter vector that contains both lacZ and lux reporter genes. In this vector,S' regulatory regions containing potential promoters and translational initiation signals control lux gene expression, while lacZ, the internal control, is expressed constitutively from a synthetic mycobacterial promoter and ribosomal binding site. Relative expression levels are presented as a ratio of lux/f3-galactosidase activity. Using this vector system, the ORFI upstream regions were found to have promoter and translational initiation activity. One of the putative promoter mutations (B 11) increased expression levels in M. smegmatis 8-fold, a second mutant (TN536) increased expression levels 4-fold, and the last mutant (B2) had a <2-fold effect on promoter activity.
InhA promoter mutations do not confer resistance on sensitive M tuberculosis. To test more directly the hypothesis that such promoter mutations were responsible for INH resistance, we amplified the ORFl-inhA region by PCR from 2 lNH-resistant clinical isolates (B2 and B 11) and wild type M tuberculosis Erdman. The entire DNA sequence of inhA and the region upstream of ORF1 were determined following cloning of the PCR products for each clone to eliminate the possibility of PCR-induced sequence changes. Since the chromosomal copy in the clinical isolates represents a single-copy allele, the inhA regions were cloned onto the integrating, single-copy vector pMV306 [19] and then transformed into both M smegmatis and M tuberculosis. The INH resistance profiles of the resulting transformants indicate that these inhA operon mutations had no measurable effect on M smegmatis and had only a modest effect at 0.1 ,ug/mLINH on M tuberculosis (figure 2). Similar levels of sensitivity were observed in M. smegmatis for transformants containing either vector control, wild-type, or mutated inhA sequences. Moreover, all three M tuberculosis transformants did not survive at 1 ,uglmL INH, although the parental clinical isolates were resistant to this drug concentration. This was confirmed by submitting the parent, vector-containing strain and the various inhA region clones to drug-susceptibility testing by an independent clinical laboratory that scored strains containing all three inhA region clones as INH-susceptible.
Discussion
The evidence that InhA is the target for activated INH in M smegmatis is compelling. Both genetic selection [12] and in vitro assays [15, 20] have established that InhA is inhibited by a metabolite derived from activation ofINH by KatG. However, the present data do not seem to support the extension that InhA is the most significant target in the tuberculosis complex organisms. The unique and exquisite sensitivity of these organisms is presumptive evidence that either the targets or the mode of activation of the prodrug must differ. Since even low-level expression of KatG from E. coli can restore partial INH sensitivity on KatG-impaired M. tuberculosis, it seems unlikely that intrinsic differences in the KatG proteins are responsible for the dramatic difference in susceptibilities [21] . Thus, the differential sensitivity may reflect differences in the relative sensitivities of the targets.
An examination of the lipid biosynthetic profiles for each organism following treatment with INH suggests that this presumption is correct. In M. smegmatis, the lipid profiles are exactly as would be predicted if InhA is the relevant target. [22] . In our hands, we have been unable to demonstrate convincingly any appreciable levels of INH resistance associated with transforming organisms of the tuberculosis complex with the wild type InhA locus on a multicopy plasmid. This was true whether the transforming DNA was from a library of mycobacterial sequences or was purified plasmid-containing InhA. It is also significant that both the wild type inhA gene and the inhA gene from the in vitro-selected INH-resistant mutant Ser94Ala can confer resistance on M. smegma tis, although the level of resistance may differ slightly [12] . Thus, resistance seems to be determined more by expression level in M. smegma tis than by the presence of a particular mutation.
The tentative identification of inhA as a potential target for INH in the tuberculosis complex has generated an enthusiastic search for patient isolates mutated in this gene [8, 18, 23, 24] . Although hundreds of isolates have been screened, few polymorphisms in the structural gene have been identified, and none has conferred resistance when moved to a susceptible host. A number of INH-resistant clinical isolates have been identified with mutations in putative inhA promoter sequences. It has been speculated that these mutations cause overexpression of InhA, which results in increased resistance to INH [7, 12, 18] .
Our studies with the pMH66 reporter vector demonstrate that up-regulation can be associated with mutations in the region upstream of inhA. However, the extent of up-regulation varies considerably with the specific mutation. M. tuberculosis strains transformed with an integrative vector containing mutated inhA regulatory regions show only small changes in their sensitivity to INH. In similar assays, M. smegmatis transformed with single-copy alleles of mutant InhA loci are not significantly resistant to INH. This result may indicate that different promoter elements are recognized in M. smegmatis and also raises the caveat to these studies that the promoter activity of the inhA upstream region may differ in its native chromosomal location in M tuberculosis.
It remains unclear to what extent inhA mutations co-occur with katG mutations; by some reports it is clear that many of the observed mutations occur in strains with very high MICs, consistent with the absence of KatG [23] . In other reports, InhA promoter mutations occur in the context of multidrugresistant strains with unspecified levels of INH resistance [24] . In such complex backgrounds, it is clearly necessary to establish the function of each mutation individually and in relation to the metabolism of the drug-resistant organism. Perhaps the observed changes in inhA loci may be related to compensatory mutations in lipid metabolism in a katG background similar to the compensatory changes in enzymes of the oxidative stress regulon recently reported [25] . Such mutations may even confer enhanced resistance to INH in a KatG-impaired background, which might not be obvious when tested in wild type M. tuberculosis but which may have clinical significance.
In summary, the biochemical, genetic, and clinical data do not support the contention [12] that InhA is the most sensitive target for the activated form of INH in M. tuberculosis. The most consistent interpretation of the data is that a currently unidentified protein involved in the production of unsaturated 24-carbon fatty acids is directly or indirectly inhibited by KatGactivated INH in the uniquely INH-sensitive M. tuberculosis.
